{
  "ptid_time": "022_S_2087_2012-11-02",
  "img_path": "/data/qiuhui/data/adni/images/022_S_2087/2012-11-02/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 21,813 mm³, 43.4% below the reference mean. With a Z-score of -1.04 (14.9th percentile), this represents mild atrophy; hippocampal volume measures 8,485 mm³, 12.2% above the reference mean. With a Z-score of 1.19 (88.4th percentile), this represents mild enlargement; whole brain volume measures 1,061,380 mm³, 1.7% below the reference mean. With a Z-score of -0.22 (41.4th percentile), this represents normal volume ; entorhinal cortex volume measures 3,078 mm³, 24.9% below the reference mean. With a Z-score of -1.69 (4.5th percentile), this represents moderate atrophy; fusiform gyrus volume measures 16,258 mm³, 13.7% below the reference mean. With a Z-score of -1.17 (12.2th percentile), this represents mild atrophy; middle temporal gyrus volume measures 20,744 mm³, 2.8% below the reference mean. With a Z-score of -0.25 (40.1th percentile), this represents normal volume . ",
  "text_data": "Age is 71.5 years. Gender is Male. Education: 16 years. Handedness: Right. Race: White. MMSE: 25.0. MoCA: 23.0. Logical Memory: 16.0. APOEε4 alleles: 1.0. Biomarker levels: Florbetapir (AV45): 1.50 SUVR (profound elevated); Amyloid beta: 512.70 pg/mL (mild reduced); Total tau: 452.30 pg/mL (significant elevated); Phosphorylated tau: 49.17 pg/mL (profound elevated). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The data shows moderate atrophy in the entorhinal cortex and mild atrophy in the ventricular volume and fusiform gyrus, which are regions commonly affected in Alzheimer's disease. Elevated biomarkers (Aβ, T-tau, P-tau, AV45) strongly support amyloid pathology and neurodegeneration, while cognitive scores (MMSE 25, MoCA 23) indicate mild impairment.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI) due to Alzheimer’s disease**  \n**Confidence:** **High**  \n\n*(Note: The hippocampal enlargement is atypical for AD but may reflect compensatory mechanisms or measurement variability. The overall biomarker and atrophy profile strongly aligns with early AD pathology.)*",
  "timestamp": "2025-07-26T02:12:54.033144"
}